Related Experiment Videos
Chemotherapy resistance in acute myeloid leukaemia
1Department of Hematology, Rm L407, University Hospital Rotterdam, Rotterdam, CA, 3000, The Netherlands.
Best Practice & Research. Clinical Haematology
|May 18, 2001
Abstract:
The development of refractory disease in acute myeloid leukaemia (AML) is frequently associated with the expression of one or several multidrug resistance (MDR) genes. MDR1, MRP1 and LRP have been identified as important adverse prognostic factors in AML. Recently it has become possible to reverse clinical multidrug resistance by blocking P-glycoprotein-mediated drug efflux. The potential relevance of MDR and new approaches to treat refractory disease, are discussed.